Duality Advisers’s CRISPR Therapeutics CRSP Stock Holding History

Duality Advisers’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-47,284	Closed	-$2.87M	–	573
2022 Q2	$2.87M	Buy	47,284 +29,132	+160%	+$1.71M	0.28%	118
2022 Q1	$1.14M	Buy	18,152 +4,767	+36%	+$299K	0.12%	294
2021 Q4	$1.01M	Buy	13,385 +4,416	+49%	+$386K	0.11%	292
2021 Q3	$1M	Buy	+8,969	New	+$1.13M	0.08%	350
2021 Q2	–	Sell	-4,303	Closed	-$524K	–	570
2021 Q1	$524K	Buy	+4,303	New	+$650K	0.05%	444

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Duality Advisers's CRSP Position: Q3 2022 in Review

Duality Advisers sold out of CRISPR Therapeutics (CRSP) in Q3 2022, closing a stake of 47,284 shares — an estimated $2.87M sold.

Duality Advisers first reported a position in CRSP in Q1 2021 and held it in 5 quarters. The position peaked at $2.87M in Q2 2022. 436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Duality Advisers reported no remaining CRISPR Therapeutics position as of Q3 2022 after selling out during the quarter.
Duality Advisers sold 47,284 CRISPR Therapeutics shares in Q3 2022, an estimated $2.87M.
Duality Advisers first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 5 quarters.
Duality Advisers's CRISPR Therapeutics position peaked at $2.87M in Q2 2022.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Duality Advisers's 13F filing for Q3 2022, filed 3 Nov 2022.